European Journal of Pediatrics

, Volume 170, Issue 2, pp 137–148

Clinical practice

Allergen-specific immunotherapy in children: facts and FAQs
  • Zsolt Szépfalusi
  • Saskia Gruber
  • Thomas Eiwegger
  • Eleonora Dehlink
Review

DOI: 10.1007/s00431-010-1348-7

Cite this article as:
Szépfalusi, Z., Gruber, S., Eiwegger, T. et al. Eur J Pediatr (2011) 170: 137. doi:10.1007/s00431-010-1348-7

Abstract

Allergen-specific immunotherapy (SIT) in its various application forms represents the main treatment approach of IgE-mediated allergic diseases in adults and children. Despite this clear recommendation, many particularities of products, patient characteristics, and product availability in different countries hamper the use of allergen-specific immunotherapy in particular in children. The frequently asked questions by parents, patients, and physicians are the backbone of this review. Thus, the potentials and limitations of allergen-specific immunotherapy in children and adolescents will be highlighted. IgE-mediated allergic diseases are affecting about 20% of the population. They manifest commonly early in life, and hence, the use of SIT should be considered also early in the course of the disease.

Keywords

Allergen-specific immunotherapySITSCITSLITImmunotherapyAllergenIgE-mediated allergyAllergy

Abbreviations

SIT

Allergen-specific immunotherapy

SLIT

Sublingual allergen-specific immunotherapy

SCIT

Subcutaneous allergen-specific immunotherapy

Allergoids

Chemically modified allergen extracts

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Zsolt Szépfalusi
    • 1
  • Saskia Gruber
    • 1
  • Thomas Eiwegger
    • 1
  • Eleonora Dehlink
    • 1
  1. 1.Division of Pediatric Pneumology, Allergology and Endocrinology, Department of PediatricsMedical University of ViennaViennaAustria